{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:53:22Z","timestamp":1766908402780,"version":"3.37.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004917","name":"Doosan Yonkang Foundation","doi-asserted-by":"publisher","award":["30-2023-0440"],"award-info":[{"award-number":["30-2023-0440"]}],"id":[{"id":"10.13039\/501100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtos.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:54:52Z","timestamp":1720691692000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Toxicity and efficacy of type I interferons on the ocular surface: in vitro, animal, and clinical studies"],"prefix":"10.1016","volume":"34","author":[{"given":"Young In","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hwa","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Suk","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonghwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Sun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mee Kum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-5314","authenticated-orcid":false,"given":"Joo Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtos.2024.07.002_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.jtos.2024.07.002_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1314424","article-title":"Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications","volume":"6","author":"Musella","year":"2017","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jtos.2024.07.002_bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3389\/fimmu.2020.00766","article-title":"Pathogenesis of herpes stromal keratitis: immune inflammatory response mediated by inflammatory regulators","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1674-8301(11)60014-6","article-title":"A functional type I interferon pathway drives resistance to cornea herpes simplex virus type 1 infection by recruitment of leukocytes","volume":"25","author":"Conrady","year":"2011","journal-title":"J Biomed Res"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1743-422X-2-59","article-title":"Macrophages and cytokines in the early defence against herpes simplex virus","volume":"2","author":"Ellermann-Eriksen","year":"2005","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12030437","article-title":"Role of innate interferon responses at the ocular surface in herpes simplex virus-1-induced herpetic stromal keratitis","volume":"12","author":"Ren","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.jtos.2024.07.002_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtos.2020.11.006","article-title":"Ocular surface complications of local anticancer drugs for treatment of ocular tumors","volume":"19","author":"Moon","year":"2021","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5301\/ejo.5001035","article-title":"Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study","volume":"28","author":"Blasi","year":"2018","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.07.002_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICO.0b013e3182523f61","article-title":"Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification","volume":"32","author":"Shields","year":"2013","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2024.07.002_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/APO.0000000000000104","article-title":"Topical interferon \u03b1-2b as a single therapy for primary ocular surface squamous neoplasia","volume":"4","author":"Kusumesh","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajo.2013.10.012","article-title":"Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b","volume":"157","author":"Besley","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.07.002_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification","volume":"130","author":"Shah","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"7\u20138","key":"10.1016\/j.jtos.2024.07.002_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08820538.2019.1648691","article-title":"Interferon alfa 2b for ocular surface squamous neoplasia: factors influencing the treatment response","volume":"34","author":"Kaliki","year":"2019","journal-title":"Semin Ophthalmol"},{"issue":"20","key":"10.1016\/j.jtos.2024.07.002_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3126\/nepjoph.v10i2.18574","article-title":"Management of ocular surface squamous neoplasia with topical and intralesional interferon alpha 2B in Mexicans","volume":"10","author":"Nava-Casta\u00f1eda","year":"2018","journal-title":"Nepal J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.07.002_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0000000000002350","article-title":"Interferon alfa-2b for pigmented ocular surface squamous neoplasia: a report of 8 lesions","volume":"40","author":"Kaliki","year":"2021","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.jtos.2024.07.002_bib20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ophtha.2008.01.006","article-title":"Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia","volume":"115","author":"Sturges","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jtos.2024.07.002_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ajo.2006.05.058","article-title":"Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia","volume":"142","author":"Holcombe","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2024.07.002_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/0301-4738.195010","article-title":"Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients","volume":"64","author":"Kaliki","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.07.002_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtos.2022.12.009","article-title":"Long term study of topical interferon \u03b1-2b eye drops as primary treatment of ocular surface squamous neoplasia","volume":"28","author":"Sripawadkul","year":"2023","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2008-322X.156127","article-title":"Resolution of primary acquired melanosis with atypia after treatment with topical mitomycin C and interferon alfa-2b","volume":"10","author":"Ghassemi","year":"2015","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00417-009-1189-0","article-title":"Interferon alpha for the treatment of melanocytic conjunctival lesions","volume":"248","author":"Herold","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/01676830.2015.1093509","article-title":"Evaluation of a short-term topical interferon \u03b1-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia","volume":"35","author":"Garip","year":"2016","journal-title":"Orbit"},{"issue":"11","key":"10.1016\/j.jtos.2024.07.002_bib28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00417-017-3754-2","article-title":"Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection","volume":"255","author":"Kikuchi","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2024.07.002_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.oftal.2017.03.006","article-title":"Interferon alpha-2a as alternative treatment for conjunctival squamous cell carcinoma","volume":"92","author":"Cruzado-S\u00e1nchez","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"7","key":"10.1016\/j.jtos.2024.07.002_bib30","first-page":"4659","article-title":"Topical interferon alpha 2a for ocular surface tumors","volume":"61","author":"Pe'er","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ophtha.2011.09.008","article-title":"Intralesional interferon-\u03b1 for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results","volume":"119","author":"Blasi","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib32","first-page":"51","article-title":"[A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta--efficacy and side effects]","volume":"110","author":"Fujioka","year":"2006","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jtos.2024.07.002_bib33","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/OPTH.S322378","article-title":"Is interferon \u03b1-2b 1 MillionIU\/mL truly better than tacrolimus 0.03% for steroid-resistant VKC ?: our 2-year experience at a tertiary health-care centre","volume":"15","author":"Gupta","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00003226-199505000-00017","article-title":"Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient","volume":"14","author":"Minkovitz","year":"1995","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jtos.2018.10.002","article-title":"Pathogenesis of herpes simplex keratitis: the host cell response and ocular surface sequelae to infection and inflammation","volume":"17","author":"Lobo","year":"2019","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ophtha.2006.09.024","article-title":"Treatment of Mooren's ulcer with topical administration of interferon alfa 2a","volume":"114","author":"Erdem","year":"2007","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.jtos.2024.07.002_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/bjophthalmol-2015-307411","article-title":"Treatment of partial limbal stem cell deficiency with topical interferon \u03b1-2b and retinoic acid","volume":"100","author":"Tan","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2024.07.002_bib38","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1016\/j.celrep.2020.02.062","article-title":"Mesenchymal stem and stromal cells harness macrophage-derived amphiregulin to maintain tissue homeostasis","volume":"30","author":"Ko","year":"2020","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.jtos.2024.07.002_bib39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/09273948.2015.1130844","article-title":"Transcription profiling of NOD-like receptors in the human cornea with disease","volume":"25","author":"Oh","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2024.07.002_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jtos.2021.12.012","article-title":"The Link module of human TSG-6 (Link_TSG6) promotes wound healing, suppresses inflammation and improves glandular function in mouse models of Dry Eye Disease","volume":"24","author":"Oh","year":"2022","journal-title":"Ocul Surf"},{"issue":"8","key":"10.1016\/j.jtos.2024.07.002_bib41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/02713683.2019.1597893","article-title":"Absence of therapeutic benefit of the anti-inflammatory protein TSG-6 for corneal alkali injury in a rat model","volume":"44","author":"Choi","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2024.07.002_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","article-title":"Detection of necrosis by release of lactate dehydrogenase activity","volume":"979","author":"Chan","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtos.2024.07.002_bib43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cyto.2017.03.011","article-title":"Effects of TGF\u03b21, PDGF-BB, and bFGF, on human corneal fibroblasts proliferation and differentiation during stromal repair","volume":"96","author":"Gallego-Mu\u00f1oz","year":"2017","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.jtos.2024.07.002_bib44","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":"Subconjunctival\/perilesional recombinant interferon \u03b12b for ocular surface squamous neoplasia: a 10-year review","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003226-200201000-00003","article-title":"Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b","volume":"21","author":"Schechter","year":"2002","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.jtos.2024.07.002_bib46","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjo.2006.107482","article-title":"Ocular surface toxicity associated with topical interferon alpha-2b","volume":"91","author":"Aldave","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2024.07.002_bib47","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.ophtha.2012.03.045","article-title":"Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up","volume":"119","author":"Krilis","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jtos.2024.07.002_bib48","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ophtha.2018.07.002","article-title":"Primary acquired melanosis treated with combination interferon and retinoic acid","volume":"125","author":"Ip","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.08.027","article-title":"Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex","volume":"145","author":"Finger","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00003226-198903000-00010","article-title":"Lack of toxicity of a topical recombinant interferon alpha","volume":"8","author":"Smith","year":"1989","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.jtos.2024.07.002_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jtos.2024.07.002_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.jtos.2024.07.002_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:02:56Z","timestamp":1733464976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012424000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":56,"alternative-id":["S1542012424000715"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2024.07.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"type":"print","value":"1542-0124"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and efficacy of type I interferons on the ocular surface: in vitro, animal, and clinical studies","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}